Jacob Van Naarden

Jacob Van Naarden is the President of Loxo@Lilly, Eli Lillys oncology division. He joined Lilly in 2019 following the acquisition of Loxo Oncology, where he was Chief Operating Officer. His career includes roles in biotechnology investing and investment banking at firms like Goldman Sachs. He earned his bachelors degree in Molecular Biology from Princeton University.

There is no publicly available information regarding Jacob Van Naardens personal life, interests, or hobbies outside of his professional career in oncology and biotechnology.

He played a key role in establishing Loxo@Lilly after the acquisition, aiming to merge the speed of a biotech with the resources of a large pharmaceutical company.